Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipavibart (AZD3152) for COVID-19 PrEP (NOVELLA)
NCT06057064Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sipavibart in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Sep 2023; status: completed.
02
Drugs
sipavibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06057064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057064.